Anti-inflammatory effects
[대역어] 항 염증 효과
[용어속성] Action
[용어속성] Action
DPP-4 inhibition and COVID-19: From initial concerns to recent expectations
DPP-4 억제와 코로나19: 초기 우려에서 최근 기대까지
Review
[키워드] acute respiratory syndrome
acute respiratory syndrome coronavirus
acute respiratory syndrome coronavirus 2
Admission
Admissions
Anti-inflammatory effects
Antigen
appear
benefit
best
binding domain
CD26
Clinical outcome
clinical outcomes
Clinical practice
coronavirus
coronavirus disease
Coronavirus disease 2019
COVID-19
COVID-19 patient
cytokine
Cytokine storm
Cytokine storms
diabete
diabetes
dipeptidyl peptidase
domain
enzyme
expressed
form
functional
functions
Gliptin
heterogeneous
high affinity
Host
Hypothesis
hypothetical
Immune cell
immune cells
Incretin
infections
Inflammation
inherent
inhibitor
initial
intensive care unit
intensive care units
limitation
management
Mortality
observational studies
outcome
Patient
patients with COVID-19
positive
progression
Randomized controlled trial
Randomized controlled trials
receptor
recommendation
reductions in
regulate
respiratory
responsible
retrospective
risk
Safe
safety profile
SARS-CoV-2
severe acute respiratory syndrome Coronavirus
significant reductions
susceptibility
susceptibility to infections
T-cell
the disease
type 2 diabete
Type 2 diabetes mellitus
virus
while
[DOI] 10.1016/j.diabet.2020.11.005 PMC 바로가기 [Article Type] Review
[DOI] 10.1016/j.diabet.2020.11.005 PMC 바로가기 [Article Type] Review
Observational Study of Chlorpromazine in Hospitalized Patients with COVID-19
Observational Study
[키워드] 95% CI
95% confidence interval
adjusted
Analysis
Anti-inflammatory effects
Antiviral
AP-HP
assistance
association
baseline
Characteristics
chlorpromazine
clinical marker
conducted
coronavirus disease
COVID-19
Cox regression
Cox regression model
daily dose
death
defined
disease severity
Endpoint
Follow-up
hazard ratio
Hospitalization
Hospitalized
hospitals
ICU
ICUs
indicated
Inpatient
intensive care unit
Mortality
multicenter
Multiple
multivariable Cox regression
occurred
over
Paris
Patient
patients hospitalized
performed
positive
primary analysis
primary endpoint
Probability
psychotropic medications
reduced
Retrospective study
sensitivity analysis
Standard deviation
suggested
university
Weighting
with COVID-19
[DOI] 10.1007/s40261-021-01001-0 PMC 바로가기 [Article Type] Observational Study
[DOI] 10.1007/s40261-021-01001-0 PMC 바로가기 [Article Type] Observational Study
Effect of Ergothioneine on 7-Ketocholesterol-Induced Endothelial Injury
7-케토콜레스테롤에 의한 내피 손상에 대한 에르고티오네인의 효과
Article
[키워드] 7-Ketocholesterol
addition
animals
Anti-inflammatory
anti-inflammatory effect
Anti-inflammatory effects
antioxidant
Apoptosis
Bacteria
blood-brain barrier
Blood–brain barrier
Brain
cardiovascular disease
Cell
cell viability
cholesterol
claudin
claudin-5
CNS
complications
coronavirus
COVID-19
COX2
cross
Cyclooxygenase
Cytokines
Dementia
diabetes
diet
Diseases
dose-dependent
Effect
Eicosanoids
Endothelial cell
endothelial cells
enzymatic activity
Ergothioneine
excitotoxicity
Extracellular
Free
Free radicals
fungi
Human brain
humans
IL-1β
IL-6
IL-8
increase in
increases in
Incubation
induce
Inflammation
inhibitor
management
mRNA expression
Mushrooms
Necrosis
neurodegenerative
Neuroinflammation
neurologic
Neurovascular
Neutralizing
NF-kB
nucleus
nutraceutical
oxidative stress
Oxysterols
Patient
pro-inflammatory cytokines
produced
protective effect
Proteins
reduced
significantly
stroke
thought
tight junction
Tight junction proteins
TNF-α
unlikely
Vascular
vascular dementia
viability
ZO-1
zonula
zonula occludens
[DOI] 10.1007/s12017-020-08620-4 PMC 바로가기 [Article Type] Article
[DOI] 10.1007/s12017-020-08620-4 PMC 바로가기 [Article Type] Article
Impact of intravenous lidocaine on clinical outcomes of patients with ARDS during COVID-19 pandemia (LidoCovid): A structured summary of a study protocol for a randomised controlled trial
COVID-19 대유행 중 ARDS 환자의 임상 결과에 대한 정맥내 리도카인의 영향(LidoCovid): 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약
Letter
[키워드] 1:1
24 hour
24 hours
acute renal failure
acute respiratory distress
acute respiratory distress syndrome
Admission
adverse event
adverse events
age
albumin
All participant
All participants
Anti-inflammatory effects
approved
aPTT
ARDS
Atrial fibrillation
Bacterial
Berlin
Beta
Bicarbonate
biological sample
biological samples
blinded
Blinding
blockers
blood count
bolus
bronchospasm
cardiac rhythm
Cardiogenic shock
Care
care providers
Child bearing
clinical
Clinical data
Clinical outcome
clinical study
collected
Commission
comparator
complete blood count
Complication
computer-generated
Concentration
conducted
Consumption
control group
cough
COVID-19
COVID-19 pneumonia
Covid-19 subgroup
CRP
D-dimers
delirium
diagnostic
Disease progression
disorders
dissemination
distribution
Distribution ratio
dosage
Effect
element
ethics committee
evaluate the effect
evaluated
Evolution
experimental group
extubation
ferritin
fibrinogen
FiO2
followed by
following
form
France
French
Gas exchange
HCG
Hospitalized
hypnotics
ICU
IL-6
Ileus
Impact
incidence
include
inclusion criteria
Inflammation
Inflammatory marker
inflammatory markers
intensive care
intensive care unit
interval
intervention group
intravenous
Intubated
investigator
LDH
Length
lidocaine
Local
local anaesthetics
Local anesthetics
Lymphocytes
moderate
moderate to severe
Modification
molecular mechanisms of pharmacological action
Mortality
NaCl
number
objective
Older
opioids
outcome
Pandemia
PaO2
PaO2/FiO2 ratio
parallel group
participant
Patient
patients with ARDS
PCT
Phase 3
Placebo
placebo-controlled
Platelets
Pneumonia
pneumopathy
Pneumothorax
Prevent
Primary outcome
protection
Protective
protocol
QTc
random
randomisation
randomised
randomised controlled trial
randomize
Randomized
Randomly
receive
Recovery time
recruitment
Registered
Renal Dialysis
renal failure
report
respiratory distress
RT-PCR
Sample size
SARS-CoV2 infection
secondary endpoint
Secondary endpoints
sedated
Severe acute respiratory syndrome
severe ARDS
Shock
Social Security
Social security system
sore throat
status
Stratification
stroke
Study protocol
supplementary material
surgical
syndrome
tetraplegia
thromboembolic
Thromboembolic event
timepoint
Toxicity
Treatment
Trial
Trial registration
triglycerides
troponin
two group
two groups
university
vasopressors
Ventilation
ventilator
ventilator-free day
Ventilator-free days
website
women
written Informed Consent
[DOI] 10.1186/s13063-021-05095-x PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-021-05095-x PMC 바로가기 [Article Type] Letter
Fighting the storm: could novel anti-TNFα and anti-IL-6 C. sativa cultivars tame cytokine storm in COVID-19?
폭풍과의 싸움: 새로운 항-TNFα 및 항-IL-6 C. sativa 품종이 COVID-19의 사이토카인 폭풍을 길들일 수 있습니까?
Research Paper
[키워드] acute respiratory distress
acute respiratory distress syndrome
addition
aging
anti-IL-6
anti-inflammatory effect
Anti-inflammatory effects
anti-inflammatory regimen
approach
ARDS
autoinflammatory disease
Cancer
cannabis
cascade
CCL2
cell line
complications
conditions
COVID-19
COVID-19 cytokine storm
COVID-19 disease
COVID-19 patient
COVID-19 patients
COX2
cytokine
Cytokine storm
Cytokines
death
Deleterious
disease
disease severity
down-regulation
downregulate
effective
Escalation
expression
fibroblast
fibrosis
Fighting
frailty
Gene Expression
had no
IL-6
include
induce
Inflammation
Inflammatory
Inflammatory cytokine
Initially
involved
lead
leads
lung
Lung fibrosis
medical cannabis
modulate
molecular
MOST
no effect
novel
Pathogenesis
pathway
Pathways
Prevent
pro-inflammatory cytokine
pro-inflammatory cytokines
proinflammatory cytokines
respiratory distress
responsible
rheumatological
SARS-CoV2
Seven
severe COVID-19 disease
syndrome
target
tested
therapeutic
These data
tissue
tissues
TNFα
TNFα
treat
treated
Treatment
[DOI] 10.18632/aging.202500 PMC 바로가기 [Article Type] Research Paper
[DOI] 10.18632/aging.202500 PMC 바로가기 [Article Type] Research Paper
In Silico Study of Polyunsaturated Fatty Acids as Potential SARS-CoV-2 Spike Protein Closed Conformation Stabilizers: Epidemiological and Computational Approaches
Article
[키워드] ACE2
acid
addition
angiotensin-converting enzyme 2
Anti-inflammatory effects
cell types
cells
conformation
country
COVID-19
COVID-19 complication
described
determine
DHA
environmental factor
explain
expressed
fatality
Fatality rate
fatty
help
host cell
in silico
incidence
infect
Interaction
lung
molecular docking
omega-3
omega-3 PUFA
Polyunsaturated
Potential
PUFA
receptors
reduce
reducing
reduction in
risk factor
SARS-CoV-2
SARS-COV-2 infection
spike
Spike protein
the disease
the spike protein
[DOI] 10.3390/molecules26030711 PMC 바로가기 [Article Type] Article
[DOI] 10.3390/molecules26030711 PMC 바로가기 [Article Type] Article
Protective Effects of Lactoferrin against SARS-CoV-2 Infection In Vitro
시험관 내 SARS-CoV-2 감염에 대한 락토페린의 보호 효과
Article
[키워드] analyzed
anti-inflammatory cytokine
Anti-inflammatory effects
Antiviral
antiviral immune response
antiviral immunity
Caco-2
Caco-2 cell
Caco-2 cells
COVID-19
curative
cytokine
determined by
Effect
epithelial cells
expression
Gene Expression
Genes
glycoprotein
IFNA1
IFNB1
immune
immune response
immune response gene
immunomodulatory
immunostaining
in vitro
in vitro data
Infection
inhibited
intestinal epithelial cell
intestinal epithelial cells
IRF3
IRF7
lack
lactoferrin
MAVS
moderate
non-toxic
Plaque assay
qRT-PCR
Replication
SARS-CoV-2
SARS-COV-2 infection
significantly
Support
TLR3
TLR7
treated
uninfected
virus
was determined
was performed
[DOI] 10.3390/nu13020328 PMC 바로가기 [Article Type] Article
[DOI] 10.3390/nu13020328 PMC 바로가기 [Article Type] Article
Repurposing Antimalarials to Tackle the COVID-19 Pandemic
COVID-19 전염병에 대처하기 위해 항말라리아제의 용도 변경
Review
[키워드] acts
acute respiratory syndrome
acute respiratory syndrome coronavirus
acute respiratory syndrome coronavirus 2
Anti-inflammatory effects
antimalarial
Antiviral
Artemisinin
artemisinins
artesunate
artesunate/pyronaridine
Clinical studies
clinical study
combination therapies
combination therapy
coronavirus
coronavirus disease
Coronavirus disease 2019
COVID-19
COVID-19 infections
cytokine
Cytokine storm
demonstrated
Drug repurposing
Effectiveness
Evidence
IL-6
in vitro
interleukin
interleukin-6
pyronaridine
repurposing
respiratory
SARS-CoV-2
severe acute respiratory syndrome Coronavirus
severe coronavirus disease
shown
Support
[DOI] 10.1016/j.pt.2020.10.003 PMC 바로가기 [Article Type] Review
[DOI] 10.1016/j.pt.2020.10.003 PMC 바로가기 [Article Type] Review